Recent Achievements and Ongoing Developments at BioSig Technologies

The company BioSig Technologies, a pioneer in digital signal processing and intracardiac signal visualization with its proprietary PURE EPTM System, released an update to shareholders on January 19, 2023, highlighting recent milestones and company developments.

Live Patient Cases to be Supported by BioSig’s PURE EP System During EPLive 2020

BioSig Technologies (NASDAQ: BSGM) is a medical technology company which designs and commercializes an innovative signal processing platform. Bio Sig’s signal processing platform is aimed to uncover the full range of ECG and intra-cardiac signals and to improve signal fidelity.

BioSig Technologies has recently announced that during EPLive 2020, the fifth international symposium on complex arrhythmias, its first product, the PURE EP system, would be featured in several live cases broadcast.

Ken Londoner: BioSig is a tech platform company

Connecticut company BioSig Tech, began generating revenue from product sales, last November, after winning Food & Drug Administration approval in 2018 to sell its PURE EP system.

The BioSig Tech PURE EP System Aims for Arrhythmia Market

After nearly a decade of research and development, BioSig Tech could be poised to break into the nearly $5 billion global electrophysiology market.

In the spring of 2018, the West Los Angeles-based medical device company has filed for federal approval for a medical device that can help doctors target the cells that cause arrhythmias, or irregular heartbeats, which increase the risks of cardiac problems and stroke.

This biomedical device, called PURE EP, aims to cut through the background noise of the operating room and its equipment in order to allow doctors to pinpoint parts of the heart that cause atrial fibrillation and ventricular tachycardia.